These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia. He PF; Xu ZJ; Zhou JD; Li XX; Zhang W; Wu DH; Zhang ZH; Lian XY; Yao XY; Deng ZQ; Lin J; Qian J J Cell Physiol; 2018 Sep; 233(9):6604-6614. PubMed ID: 29150948 [TBL] [Abstract][Full Text] [Related]
9. BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration. Miah S; Goel RK; Dai C; Kalra N; Beaton-Brown E; Bagu ET; Bonham K; Lukong KE PLoS One; 2014; 9(2):e87684. PubMed ID: 24523872 [TBL] [Abstract][Full Text] [Related]
10. Expression of RBM5-related factors in primary breast tissue. Rintala-Maki ND; Goard CA; Langdon CE; Wall VE; Traulsen KE; Morin CD; Bonin M; Sutherland LC J Cell Biochem; 2007 Apr; 100(6):1440-58. PubMed ID: 17131366 [TBL] [Abstract][Full Text] [Related]
11. Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia. Lee S; Roy F; Galmarini CM; Accardi R; Michelon J; Viller A; Cros E; Dumontet C; Sylla BS Oncogene; 2004 Mar; 23(13):2287-97. PubMed ID: 14730347 [TBL] [Abstract][Full Text] [Related]
12. RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis. Oh JJ; Taschereau EO; Koegel AK; Ginther CL; Rotow JK; Isfahani KZ; Slamon DJ Lung Cancer; 2010 Dec; 70(3):253-62. PubMed ID: 20338664 [TBL] [Abstract][Full Text] [Related]
13. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Wu X; Zhu Z; Li W; Fu X; Su D; Fu L; Zhang Z; Luo A; Sun X; Fu L; Dong JT Breast Cancer Res; 2012 May; 14(3):R73. PubMed ID: 22569290 [TBL] [Abstract][Full Text] [Related]
14. Transcriptional regulation of the human tumor suppressor DOK1 by E2F1. Siouda M; Yue J; Shukla R; Guillermier S; Herceg Z; Creveaux M; Accardi R; Tommasino M; Sylla BS Mol Cell Biol; 2012 Dec; 32(23):4877-90. PubMed ID: 23028047 [TBL] [Abstract][Full Text] [Related]
15. The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1. Goel RK; Miah S; Black K; Kalra N; Dai C; Lukong KE FEBS J; 2013 Sep; 280(18):4539-59. PubMed ID: 23822091 [TBL] [Abstract][Full Text] [Related]
17. Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients. Real SAS; Parveen F; Rehman AU; Khan MA; Deo SVS; Shukla NK; Husain SA BMC Cancer; 2018 Jul; 18(1):711. PubMed ID: 29970036 [TBL] [Abstract][Full Text] [Related]
18. DOK1/PPARgamma pathway mediates anti-tumor ability of all-trans retinoic acid in breast cancer MCF-7 cells. Ding X; Wang W; Wang M; Wu J; Yao F Biochem Biophys Res Commun; 2017 May; 487(2):189-193. PubMed ID: 28396148 [TBL] [Abstract][Full Text] [Related]
19. DOK1 mediates SHP-2 binding to the alphaVbeta3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. Ling Y; Maile LA; Badley-Clarke J; Clemmons DR J Biol Chem; 2005 Feb; 280(5):3151-8. PubMed ID: 15546884 [TBL] [Abstract][Full Text] [Related]
20. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]